Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation

American Journal of Cardiology

Volumn 107, Issue 3, 2011, Pages 387-392

  Thongtang, Nuntakorn ^a   Ai, Masumi ^a   Otokozawa, Seiko ^a   Himbergen, Thomas V ^a   Asztalos, Bela F ^a   Nakajima, Katsuyuki ^a   Stein, Evan ^b   Jones, Peter H ^c   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b Metabolic and Atherosclerosis Research Center   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ATORVASTATIN; C REACTIVE PROTEIN; GLYCOSYLATED ALBUMIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DIABETES MELLITUS; FEMALE; FLUOROBENZENES; GLUCOSE; HEPTANOIC ACIDS; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INSULIN; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SERUM ALBUMIN; SULFONAMIDES; TRIGLYCERIDES;

EID: 78951481453     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.09.031     Document Type: Article

References (25)

1. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, E. Miller, V.A. Cain, and J.W. Blasetto Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR (*) Trial) Am J Cardiol 92 2003 152 160
2. P.H. Jones, D.B. Hunninghake, K.C. Ferdinand, E.A. Stein, A. Gold, R.J. Caplan, and J.W. Blasetto Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial Clin Ther 26 2004 1388 1399
3. B.F. Asztalos, F. Le Maulf, G.E. Dallal, E. Stein, P.H. Jones, K.V. Horvath, F. McTaggart, and E.J. Schaefer Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins Am J Cardiol 99 2007 681 685
4. M. Ai, S. Otokozawa, B.F. Asztalos, K. Nakajima, E. Stein, P.H. Jones, and E.J. Schaefer Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels Am J Cardiol 101 2008 315 318
5. S. Otokozawa, M. Ai, T. Van Himbergen, B.F. Asztalos, A. Tanaka, E.A. Stein, P.H. Jones, and E.J. Schaefer Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels Atherosclerosis 205 2009 197 201
6. T.M. van Himbergen, N.R. Matthan, N.A. Resteghini, S. Otokozawa, M. Ai, E.A. Stein, P.H. Jones, and E.J. Schaefer Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers J Lipid Res 50 2009 730 739
7. M.S. Sabatine, S.D. Wiviott, D.A. Morrow, C.H. McCabe, and C.P. Cannon High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy Circulation 110 2004 III-834
8. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr, J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, and R.J. Glynn Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
9. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. MacFarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, and I. Ford Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
10. M. Okada, H. Matsui, Y. Ito, A. Fujiwara, and K. Inano Low-density lipoprotein cholesterol can be chemically measured: a new superior method J Lab Clin Med 132 1998 195 201
11. H. Sugiuchi, Y. Uji, H. Okabe, T. Irie, K. Uekama, N. Kayahara, and K. Miyauchi Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin Clin Chem 41 1995 717 723
12. M. Ai, S. Otokozawa, B.F. Asztalos, Y. Ito, K. Nakajima, C.C. White, L.A. Cupples, P.W. Wilson, and E.J. Schaefer Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study Clin Chem 56 2010 967 976
13. T. Kouzuma, T. Usami, M. Yamakoshi, M. Takahashi, and S. Imamura An enzymatic method for the measurement of glycated albumin in biological samples Clin Chim Acta 324 2002 61 71
14. T. Kouzuma, Y. Uemastu, T. Usami, and S. Imamura Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method Clin Chim Acta 346 2004 135 143
15. A. Nishimura, and T. Sawai Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer Clin Chim Acta 371 2006 163 168
16. M. Ai, S. Otokozawa, E.J. Schaefer, B.F. Asztalos, K. Nakajima, P. Shrader, S. Kathiresan, J.B. Meigs, G. Williams, and D.M. Nathan Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus Clin Chim Acta 406 2009 71 74
17. A. Nishimura ST evaluation and clinical significance of latex immunoassay (LIA) of insulin using the routine biochemical AutoAnalyzer Jpn J Clin Chem 35 2006 48 53
18. K.K. Koh, M.J. Quon, S.H. Han, Y. Lee, S.J. Kim, and E.K. Shin Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients J Am Coll Cardiol 55 2010 1209 1216 23
19. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, and R. Simes Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
20. C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, and E. Braunwald Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445
21. M.S. Kostapanos, H.J. Milionis, A.D. Agouridis, C.V. Rizos, and M.S. Elisaf Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose Int J Clin Pract 63 2009 1308 1313
22. W.L. Baker, R. Talati, C.M. White, and C.I. Coleman Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis Diabetes Res Clin Pract 87 2010 98 107
23. C.I. Coleman, K. Reinhart, J. Kluger, and C.M. White The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials Curr Med Res Opin 24 2008 1359 1362
24. A.Y. Her, J.Y. Kim, S.M. Kang, D. Choi, Y. Jang, N. Chung, I. Manabe, and S.H. Lee Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism J Cardiovasc Pharmacol Ther 15 2010 167 174
25. M. Nakata, S. Nagasaka, I. Kusaka, H. Matsuoka, S. Ishibashi, and T. Yada Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control Diabetologia 49 2006 1881 1892